Diabetes

In the first episode of the podcast, Jennifer Goldman and Hailey Choi discuss the latest FDA updates around compounded weight loss medications, clinical concerns and how pharmacists can protect their patients.

This method supports improved, early detection for diabetes without relying on blood samples or complex procedures.

Further, the authors of the “Standards of Care in Diabetes 2025” highlighted the benefits of continuous glucose monitoring systems and recommend initiating these as soon as possible.

The authors emphasize the importance of multifaceted and team-based approaches to the management of diabetes.

Investigators find that orforglipron lowered A1c by an average of 1.3% to 1.6% from a baseline of 8% across 3 different dosages.

Furthermore, C-reactive protein has greater prognosis for lung cancer, colorectal cancer, and ovarian cancer.

A conversation with Scott Biggs and Greg Mitchell at the American Associated Pharmacies 2025 Annual Conference.

Pharmacists have positive impacts on health outcomes for diabetes and patients using CGM devices, including reductions in A1c.

Hypertension and obstructive sleep apnea are considered independent risk factors for cardiovascular diseases as well as diabetes.

Further studies are needed to further confirm the association between glucagon-like peptide 1 medication and reductions in dementia risk.

Type 1 diabetes can cause long-term complications, including the development of autoimmune diseases.

Clinical pharmacists counsel patients during the intervention and make informed medication changes based on the data received from continuous glucose monitoring (CGM).

With expertise in the management and treatment of diabetes, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, shared her insights on counseling patients using GLP-1 medications.

As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.

All 3 types of virtual diabetes self-management interventions lead to better results in hemoglobin A1c over a 6-month period.

The integration of CGM into pharmacy practice represents a significant opportunity for pharmacists to provide enhanced patient care.

The outpatient endoscopic procedure modifies duodenal dysfunction and restores metabolic health.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, joined Drug Topics to discuss which indications patients typically gravitate toward for the use of GLP-1 medications.

Lindsey Miller, PharmD, clinical assistant professor of pharmacy practice at the University of Mississippi, discusses how pharmacists can help patients understand and effectively use continuous glucose monitoring.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, associate director of experiential education at the College of Pharmacy at Midwestern University, also addresses personalized care and the expanding responsibilities of pharmacists.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, associate director of experiential education at the College of Pharmacy at Midwestern University, discusses recent advancements in diabetes care.

Heather Johnson, PharmD, BCACP, CTTS, and Heather Roth, BSPharm, RPh, discuss medications and devices used for improving cardiovascular health among patients with or without diabetes.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses the various errors patients experience when using CGM devices.

Heather Johnson, PharmD, BCACP, CTTS, and Heather Roth, BSPharm, RPh, compare patients’ diabetes outcomes in clinical and community pharmacy settings.

Control-IQ+ was associated with a greater reduction in glycated hemoglobin compared to a continuous glucose monitor alone.